Dr. Said Khader discusses the once-a-week GLP-1 RA option Dulaglutide with a focus on the cardiovascular benefits of the therapy for T2DM patients.
To understand:
- Different cardiovascular trials design and patient population distribution
- The difference between primary and secondary CV protection
- Understand the results of recent CV trials for Dulaglutide and its implications on T2DM patients
FREE
Free